NCT07000955View on ClinicalTrials.gov

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 17, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

May 14, 2027

Conditions

Obesity

Interventions

DRUG

Tirzepatide

Tirzepatide administered subcutaneously (SC) once a week.

DRUG

Placebo

Placebo administered subcutaneously (SC) once a week.

DRUG

IBI362

IBI362 administered subcutaneously (SC) once a week.

Trial Locations (1)

210003

RECRUITING

The Affiliated Hospital of Nanjing University Medical School, Nanjing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT07000955 - Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity | Biotech Hunter | Biotech Hunter